NEWAMSTERDAM PHARMA CO NV(NASDAQ:NAMS) stock News

NAMS Latest News, Press Relases and Analysis

All

Press Releases

3 days ago - By: Menarini Industrie Farmaceutiche Riunite

Evropská agentura pro léčivé přípravky (EMA) přijala od skupiny Menarini Group žádost o registraci přípravků Obicetrapib a Obicetrapib/Ezetimib pro léčbu dospělých pacientů s primární hypercholesterolemií (heterozygotní familiární a nefamiliární) nebo

3 days ago - By: Menarini Industrie Farmaceutiche Riunite

Заявки на получение регистрационного удостоверения обицетрапиба и обицетрапиба/эзетимиба от Menarini Group, принятые для рассмотрения Европейским агентством по лекарственным средствам (EMA) для лечения взрослых с первичной гиперхолестеринемией

3 days ago - By: Menarini Industrie Farmaceutiche Riunite

Wnioski o pozwolenie na dopuszczenie do obrotu leków Obicetrapib i Obicetrapib/Ezetimibe firmy Menarini Group zostały przyjęte do rozpatrzenia przez Europejską Agencję Leków (EMA) w zakresie leczenia dorosłych z pierwotną hipercholesterolemią

3 days ago - By: Menarini Industrie Farmaceutiche Riunite

Die Zulassungsanträge der Menarini Group für Obicetrapib und Obicetrapib/Ezetimibe zur Behandlung von Erwachsenen mit primärer Hypercholesterinämie (heterozygote familiäre und nicht-familiäre Form) oder gemischter Dyslipidämie wurden von der Europäischen

12 days ago - By: Benzinga

Expert Outlook: NewAmsterdam Pharma Co Through The Eyes Of 6 Analysts

a month ago - By: Benzinga

What 5 Analyst Ratings Have To Say About NewAmsterdam Pharma Co

a month ago - By: The Motley Fool

NewAmsterdam (NAMS) Q2 Revenue Jumps 49%

3 days ago - By: Menarini Industrie Farmaceutiche Riunite

Les demandes d'autorisation de mise sur le marché de l'obicetrapib et de l'obicetrapib/ézétimibe de Menarini Group ont été acceptées pour examen par l'Agence européenne des médicaments (EMA) pour le traitement des adultes atteints d'hypercholestérolémie

4 days ago - By: Menarini Industrie Farmaceutiche Riunite

Aceptadas las solicitudes de autorización de comercialización de obicetrapib y obicetrapib/ezetimiba

4 days ago - By: Menarini Industrie Farmaceutiche Riunite

Menarini Group's Obicetrapib and Obicetrapib/Ezetimibe Marketing Authorisation Applications Accepted for Review by the European Medicines Agency (EMA) for the Treatment of adults with primary hypercholesterolaemia (heterozygous familial and non-familial)

12 days ago - By: NewAmsterdam Pharma N.V.

NewAmsterdam Pharma to Participate in Upcoming Medical Meeting and Investor Conferences in September

12 days ago - By: NewAmsterdam Pharma N.V.

NewAmsterdam Pharma to Participate in Upcoming Medical Meeting and Investor Conferences in September

13 days ago - By: Piramal Pharma Solutions

Piramal Pharma Solutions und NewAmsterdam Pharma investieren in einen spezialisierten Produktionsbereich, um die Herstellungskapazitäten fester oraler Darreichungsformen am Piramal-Standort in Sellersville, Pennsylvania, zu erweitern

15 days ago - By: Piramal Pharma Solutions

Piramal Pharma Solutions et NewAmsterdam Pharma investissent dans une unité dédiée pour améliorer les capacités de production de dosages solides oraux sur le site de Piramal à Sellersville, en Pennsylvanie.

16 days ago - By: Piramal Pharma Solutions

Piramal Pharma Solutions and NewAmsterdam Pharma Invest in Dedicated Suite to Enhance Oral Solid Dosage Production Capabilities at Piramal's Sellersville, Pennsylvania Site

19 days ago - By: NewAmsterdam Pharma N.V.

NewAmsterdam Announces Acceptance of Marketing Authorization Applications for Review by European Medicine Agency for Obicetrapib

19 days ago - By: NewAmsterdam Pharma N.V.

NewAmsterdam Announces Acceptance of Marketing Authorization Applications for Review by European Medicine Agency for Obicetrapib

a month ago - By: Zacks Investment Research - Mentions: ASRT

NewAmsterdam Pharma Company N.V. (NAMS) Reports Q2 Loss, Tops Revenue Estimates

a month ago - By: NewAmsterdam Pharma N.V.

NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results

a month ago - By: NewAmsterdam Pharma N.V.

NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results

a month ago - By: NewAmsterdam Pharma N.V.

NewAmsterdam Pharma Presents Positive Data from BROADWAY Trial Demonstrating Statistically Significant Reductions in Key Alzheimer’s Disease Biomarkers at AAIC 2025

a month ago - By: NewAmsterdam Pharma N.V.

NewAmsterdam Pharma Presents Positive Data from BROADWAY Trial Demonstrating Statistically Significant Reductions in Key Alzheimer’s Disease Biomarkers at AAIC 2025

2 months ago - By: NewAmsterdam Pharma N.V.

NewAmsterdam Pharma to Present Alzheimer’s Biomarker Data from BROADWAY Trial at AAIC 2025

3 months ago - By: Yahoo Finance - Mentions: BBIO AAPL NVDA